Home News Company in the news

iX Biopharma enters China market with licensing agreement for erectile dysfunction drug

Felicia Tan
Felicia Tan4/27/2020 09:36 AM GMT+08  • 2 min read
iX Biopharma enters China market with licensing agreement for erectile dysfunction drug
iX Biopharma has entered into a 10-year licensing agreement with Yiling Pharmaceutical in China for the licensing, supply, and distribution of Wafesil, a fast-dissolving sublingual sildenafil wafer for the treatment of male erectile dysfunction.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (Apr 27): iX Biopharma has entered into a 10-year licensing agreement with Yiling Pharmaceutical in China for the licensing, supply, and distribution of Wafesil, a fast-dissolving sublingual sildenafil wafer for the treatment of male erectile dysfunction.

See also: iXBiopharma's Wafesil granted regulatory approval for treatment of male erectile dysfunction in Australia

Wafesil was formerly known as PheoniX.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now